HCAPPED I: HCAP-Pcr in Emergency Department

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

93 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-07

Study Completion Date

2026-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective Observational Study (on Diagnostic Procedure) - Single-Center, Non-Profit.

A pilot study will be conducted on a prospective cohort of patients with HCAP (Healthcare-Associated Pneumonia). This study will be conducted on a single arm of patients. No control group or randomization is planned.

The use of syndromic molecular panels in pneumonias with risk factors for MDR (multidrug-resistant) pathogens, such as in patients with HCAP, has become common practice. However, the use of this tool is reserved for patients with severe forms of HCAP (PIRO\>2, at least moderate ARDS, and respiratory failure requiring high-flow oxygen during sepsis) (30), and it is not yet standardized by international guidelines. The decision to use this tool or not is currently at the clinician\'s discretion and is usually reserved for the severe forms mentioned above. The study aims to determine if the early use of this tool has a real benefit on the management of antibiotic therapy for these patients in terms of therapeutic changes compared to corporate and international guidelines.

Duration of patient enrollment: 1 year. Duration of the study: 1.5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Multiplex PCR in CAP

NCT06097117

Community-acquired Pneumonia

UNKNOWN

Value of Flow Cytometry in Infectious Point of Care: Feasibility Study

NCT03912870

A Potential Infectious Respiratory Clinical Syndrome Potential Clinical Urinary Infectious Syndrome A Potential Clinical Abdominal Infection Syndrome

COMPLETED

Clinical Characteristics of Acutely Hospitalized Adults With Community-acquired- Pneumonia

NCT04681963

Pneumonia

COMPLETED

Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR

NCT00275691

Cough Fever

COMPLETED

Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment

NCT06028217

Hospital-acquired Pneumonia Antibiotic Resistant Infection

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia Bronchoalveolar Lavage Antimicrobial Treatment Sputum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PCR multiplex (BIOFIRE® FILMARRAY® Pneumonia plus Panel)

The study seeks to assess the utility of molecular diagnostic tests in the emergency department for the microbiological etiological diagnosis of healthcare-associated pneumonia (HCAP).

In clinical practice, patients with respiratory and infectious symptoms undergo blood sample collection for blood gas, chemical-physical, and culture analyses, urine samples for urinary antigen testing, and imaging diagnostics (X-ray, CT, ultrasound). Due to local infection control and surveillance measures, all patients with respiratory symptoms undergo a nasopharyngeal antigen test for SARS-CoV-2 as part of standard clinical practice.

After completing the diagnostic work-up and diagnosing HCAP pneumonia, endobronchial samples are typically collected for multiplex PCR testing (BIOFIRE® FILMARRAY® Pneumonia plus Panel). Patients from whom these samples are collected are those needing high-flow oxygen therapy (VM35 or FiO2 higher, Reservoir, HFNC, NIV, CPAP), undergoing IOT, SOFA ≥2, PaO2/FiO2 \< 200, o

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients over the age of 18 who undergo bronchoalveolar lavage (BAL) in the Emergency Department (DEA), with a Rankin score of less than 5, and who are admitted to the Emergency Department with a diagnosis of healthcare-associated pneumonia (HCAP) of bacterial, viral, or fungal origin. The diagnosis must be confirmed by clinical and radiological criteria according to the IDSA guidelines, which include: New pulmonary infiltrate on chest X-ray, Evidence that the infiltrate is of infectious origin, At least two of the following three clinical signs: Fever higher than 38 °C, Leukocytosis or leukopenia, Purulent secretions.

Additionally, patients must meet at least one of the following criteria:

* Need for high-flow oxygen therapy (VM35 or FiO2 \>35%, Reservoir, HFNC, NIV, CPAP)
* Intubation (IOT)
* SOFA score ≥2 or PSI score \>85 (age 75 + IR)
* Horowitz index (PaO2/FiO2) \< 200

Exclusion Criteria

* Lack of consent
* Age under 18 or over 90
* Pregnancy
* Life expectancy less than 3 months
* Hospital admission \>48 hours (hospital-acquired pneumonia - HAP)
* Rankin score ≥ 5
* Community-acquired pneumonia (CAP)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No